Venglustat, Lanreotide Acetate, and Tolvaptan as therapeutic options for the treatment of autosomic dominant polychistic kidney disease: a narrative review
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.7246Keywords:
Autosomal dominant polycystic kidney disease, ADPKD, polycystic kidney disease, Tolvaptan, V2 receptor antagonists, Venglustat, glucosylceramide synthase inhibitor, lanreotide acetate, somatostatin analogAbstract
Introduction: autosomal polycystic kidney disease (ADPKD) is a hereditary orphan disease, with an average world prevalence of 2.7 per 100,000 inhabitants. Until recently, treatment was limited to the control of clinical manifestations, but since 2015 with the appearance of tolvaptan, the disease has been managed and the introduction of venglustat and lanreotide acetate as treatment makes it necessary to review therapeutic options.
Methods: narrative review in PubMed, Cochrane Library, OVID, EBSCO and Google Scholar.
Results: Were obtained 92 articles in the search strategy, of which five were included in the qualitative analysis. The TEMPO 3: 4 Study showed that tolvaptan reduced the annual growth rate in the total kidney volume from 5.5% to 2.8% (p <0.001), reducing the deterioration of the filtration rate. Glomerular tissue estimated at −3.70 to −2.72 mL/min/1.73 m2 (p <0.001) compared to placebo. THE DIPAK 1: evidence that lanreotide reduces kidney volume compared to placebo (4.15% vs. 5.56%; per year; 95% CI: -2.41% to -0.24%; p= 0.02). Venglustat clinical trials showed preliminary improvement in the annualized rate of change in total kidney volume (TKV) and estimated glomerular filtration rate (eGFR), according to the results of preclinical studies, however, they are still in study.
Conclusions: ADPKD is a pathology with few therapeutic options and with recent treatments incorporated, currently under investigation. This article sets the guide for future study design quantitative.
Downloads
References
Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. Remuzzi G, editor. PLoS One. 2018; 13(1): e0190430. Doi: 10.1371/journal.pone.0190430.
Iliuta I-A, Kalatharan V, Wang K, Cornec-Le Gall E, Conklin J, Pourafkari M, et al. Polycystic kidney disease without an apparent family history. J Am Soc Nephrol. 2017; 28(9): 2768–76. doi: 10.1681/ASN.2016090938.
Zhou Z, Xu Y, Delcourt C, Shan J, Li Q, Xu J, et al. Is regular screening for intracranial aneurysm necessary in patients with autosomal dominant polycystic kidney disease? a systematic review and meta-analysis. Cerebrovasc Dis. 2017; 44(1–2): 75–82. doi: 10.1159/000476073.
Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002; 40(3): 611–22. doi: 10.1053/ajkd.2002.34924.
Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B. End-stage renal disease in autosomal dominant polycystic kidney disease: A comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clin Outcomes Res. 2015; 7: 65–72. doi: 10.2147/CEOR.S76269.
Ong ACM, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015; 385(9981): 1993–2002. Doi: 10.1016/S0140-6736(15)60907-2
McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): The ADPKD outcomes model. BMC Nephrol. 2018;19(1): 1–12. doi: 10.1186/s12882-017-0804-2.
Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation Lanreotide acetate for the treatment of autosomal dominant polycystic kidney disease. EMA/COMP/432098/2015, European Medicines Agency; 2015. Disponible en: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/15/1514-public-summary-opinion-orphan-designation-lanreotide-acetate-treatment-autosomal-dominant_en.pdf.
European Medicines Agency. Public summary of opinion on orphan designation Venglustat for the treatment of autosomal dominant polycystic kidney disease. EMA/840293/2018, European Medicines Agency; 2019. Disponible en: https://www.ema.europa.eu/en/documents/orphan-review/eu/3/18/2122-public-summary-opinion-orphan-designation-venglustat-treatment-autosomal-dominant-polycystic_en.pdf.
Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10(1): 86–98. doi: 10.1002/cpdd.865.
Meijer E, Visser FW, Van Aerts RMM, Blijdorp CJ, Casteleijn NF, D’Agnolo HMA, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease the DIPAK 1 randomized clinical trial. JAMA. 2018; 320(19): 2010–9. doi: 10.1001/jama.2018.15870.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018; 29(10): 2458–70. Doi: 10.1681/ASN.2018060590
Bae KT, Czerwiec FS, Gansevoort RT, Ouyang JJ, Torres VE, Chapman AB, et al. Rationale and design of the TEMPO (Tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study. Am J Kidney Dis. 2011; 57(5): 692–9. Available from: doi: 10.1053/j.ajkd.2010.11.029
Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, et al. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis. 2017; 69(2): 210–9. Available from: doi: 10.1053/j.ajkd.2016.08.028.
Wyatt CM, Le Meur Y. REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney Int. 2018; 93(2): 292–5. Available from: doi: 10.1016/j.kint.2017.12.002
Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, Van Den Born J, Tonnis WF, et al. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrology. 2018; 19: 368. Doi: 10.1186/s12882-018-1176-y.
Genzyme. Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of GZ/SAR402671 in patients at risk of rapidly progressive autosomal dominant polycystic kidney disease (ADPKD). ClinicalTrials.gov. ClinicalTrials.gov Identifier: NCT03523728; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03523728.
Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010; 16(7): 788–92. doi: 10.1038/nm.2171.
Myint TM, Rangan GK, Webster AC. Treatments to slow progression of autosomal dominant polycystic kidney disease: Systematic review and meta-analysis of randomized trials. Nephrology. 2014; 19(4): 217–26. doi: 10.1111/nep.12211.
Downloads
Published
Versions
- 2023-07-18 (3)
- 2021-04-12 (2)
- 2020-12-30 (1)
Issue
Section
License
Copyright (c) 2020 Interdisciplinary Journal of Epidemiology and Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
